RBC Capital Markets BioTech Analyst Michael Yee and CastleArk Management President & CIO Jerry Castellini discuss the bull and bear cases for biotech stocks.» Read More
Ex-CEO Shkreli will talk to his followers on social media, but not to Congress, which is asking for testimony on drug prices. The NYT reports.
The Nasdaq biotech index traded lower following a tweet from Hillary Clinton disparaging higher drug prices, reports CNBC's Meg Tirrell.
Former Medtronic CEO Bill George matches up industry competitors and offers up this scorecard of CEOs with solid strategies that are worth betting on.
Valeant's ailing CEO, Michael Pearson, said he was on the road to recovery but was uncertain about when he would return from medical leave.
Cigna said the suspension does not affect members currently enrolled in these plans.
Former drug executive Martin Shkreli has a plan if he is forced to appear at a congressional hearing about drug prices.
Valeant's interim chairman and CEO say the pharma giant is making changes in "a number of areas" to "correct our missteps."
The controversial former drug exec, facing fraud charges, is also objecting to being a called a "pharma bro."
Peder Holk Nielsen, CEO of Novozymes, explains why the company has downgraded its outlook for sales growth.
Health care CEOs discuss the three traits they believe define what makes a good leader.
Health care CEOs discuss what they believe defines success in the pharmaceutical and biotech industries.
Len Yaffe, Stoc Doc Partners, weighs in on biotech's best bets.
JMP Securities President Mark Lehmann explains why now is the time to get in on biotech stocks.
CNBC's Bertha Coombs highlights the big Nasdaq laggards as biotech concerns weigh.
After selling off more than 5 percent, RBC Capital Markets' Michael Yee discusses the state of biotech.
David Agus, "The Lucky Years" author, discusses how innovative health technology could help prevent some diseases and actually increase life expectancy.
Drug costs continue to rise and will only get worse moving forward, one expert contended Tuesday.
Bristol-Myers Squibb CEO Dr. Giovanni Caforio, provides insight to his company's position in the biotech industry, and the thinking about pricing in cancer drugs.
BioMarin CEO Jean-Jacques Bienaime, discusses drug pricing, the sentiment of investors in biotech and his expectations for the company's Duchenne muscular dystrophy drug.
Checking on the biotech industry, and the outlook for ARIAD Pharmaceuticals, with Alex Denner, Sarissa Capital Management founder and CIO.
Get the best of CNBC in your inbox